{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:06:53Z","timestamp":1780668413554,"version":"3.54.1"},"reference-count":107,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Neglected Tropical Diseases (NTD) are chronic infectious conditions\nthat primarily affect marginalized populations. The chemotherapeutic arsenal\navailable for treating NTD is limited and outdated, which poses a challenge in controlling\nand eradicating these diseases. This is exacerbated by the pharmaceutical industry's\nlack of interest in funding the development of new therapeutic alternatives. In addition,\na considerable number of drugs used in NTD therapy have low aqueous solubility.\nTo address this issue, solubility enhancement strategies, such as the use of inclusion\ncomplexes with cyclodextrins (CD) can be employed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Therefore, this systematic review aims to present the application of CD in\ncomplexing with drugs and chemotherapeutic compounds used in the therapy of some of\nthe most prevalent NTD worldwide and how these complexes can enhance the treatment\nof these diseases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Two bibliographic databases, Science Direct and PubMed, were used to\nconduct the search. The selection of studies and the writing of this systematic review followed\nthe criteria outlined by the PRISMA guidelines.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>From a total of 978 articles, 23 were selected after applying the exclusion criteria.\nAll the studies selected were consistent with the use of CD as a strategy to increase\nthe solubility of therapeutic agents used in NTD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The results indicate that CD can enhance the solubility of chemotherapeutic\nagents for the treatment of Neglected Tropical Diseases (NTD). This review presents\ndata that clearly highlights the potential use of CD in the development of new treatments\nfor neglected tropical diseases. It can assist in the formulation of future treatments that\nare more effective and safer.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298673318410240627031819","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:15:49Z","timestamp":1720091749000},"page":"3466-3492","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cyclodextrins as a Strategy for Enhancing Solubility of Therapeutic Agents for Neglected Tropical Diseases: A Systematic Review"],"prefix":"10.2174","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8486-5578","authenticated-orcid":true,"given":"Demis Ferreira","family":"de Melo","sequence":"first","affiliation":[{"name":"Laboratory of Drug Technology, Department of Pharmaceutical Sciences, Federal University of Pernambuco.\nAv. Prof. Artur de S\u00e1 - Cidade Universit\u00e1ria, Recife, Pernambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2195-8440","authenticated-orcid":true,"given":"Larissa Pereira","family":"Alves","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Technology, Department of Pharmaceutical Sciences, Federal University of Pernambuco.\nAv. Prof. Artur de S\u00e1 - Cidade Universit\u00e1ria, Recife, Pernambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-2343","authenticated-orcid":true,"given":"Natalia Millena","family":"da Silva","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Technology, Department of Pharmaceutical Sciences, Federal University of Pernambuco.\nAv. Prof. Artur de S\u00e1 - Cidade Universit\u00e1ria, Recife, Pernambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2182-7272","authenticated-orcid":true,"given":"Laysa Creusa Paes Barreto","family":"Barros Silva","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Technology, Department of Pharmaceutical Sciences, Federal University of Pernambuco.\nAv. Prof. Artur de S\u00e1 - Cidade Universit\u00e1ria, Recife, Pernambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9664-8092","authenticated-orcid":true,"given":"Bruna Fernanda","family":"de Lima Arruda Holanda","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Technology, Department of Pharmaceutical Sciences, Federal University of Pernambuco.\nAv. Prof. Artur de S\u00e1 - Cidade Universit\u00e1ria, Recife, Pernambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-5418","authenticated-orcid":true,"given":"Myla L\u00f4bo","family":"de Souza","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Technology, Department of Pharmaceutical Sciences, Federal University of Pernambuco.\nAv. Prof. Artur de S\u00e1 - Cidade Universit\u00e1ria, Recife, Pernambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2403-1026","authenticated-orcid":true,"given":"Larissa Araujo","family":"Rolim","sequence":"additional","affiliation":[{"name":"Drug, Medicine and Food\nAnalytical Center; College of Pharmaceutical Sciences, Federal University of Vale do S\u00e3o Francisco. Av.\nJos\u00e9 de S\u00e1 Mani\u00e7oba, Petrolina, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-2587","authenticated-orcid":true,"given":"Pedro Jose Rolim","family":"Neto","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Technology, Department of Pharmaceutical Sciences, Federal University of Pernambuco.\nAv. Prof. Artur de S\u00e1 - Cidade Universit\u00e1ria, Recife, Pernambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/bcp.15148","volume":"88","author":"Weld E.D.","year":"2022","unstructured":"Weld E.D.; Waitt C.; Barnes K.; Garcia Bournissen F.; Twice neglected? Neglected diseases in neglected populations. Br J Clin Pharmacol  2022,88(2),367-373","journal-title":"Br J Clin Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"622286","DOI":"10.3389\/fchem.2021.622286","volume":"9","author":"J B.","year":"2021","unstructured":"J B.; M B.M.; Chanda K.; An overview on the therapeutics of neglected infectious diseases-leishmaniasis and chagas diseases. Front Chem  2021,9,622286","journal-title":"Front Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"106212","DOI":"10.1016\/j.actatropica.2021.106212","volume":"225","author":"Sripa B.","year":"2022","unstructured":"Sripa B.; Leonardo L.; Hong S.J.; Ito A.; Brattig N.W.; Status and perspective of asian neglected tropical diseases. Acta Trop  2022,225,106212","journal-title":"Acta Trop"},{"key":"ref=4","unstructured":"World Health Organization, Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021\u20132030. 2020. Available from:  https:\/\/www.who.int\/publications\/i\/item\/9789240 052932 (accessed on 13-6-2024)"},{"key":"ref=5","year":"2021","unstructured":"World Health Organization Neglected tropical diseases  2021","journal-title":"Neglected tropical diseases"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.actatropica.2021.106210","volume":"225","author":"Ferraz L.R.M.","year":"2022","unstructured":"Ferraz L.R.M.; Silva L.C.P.B.B.; Souza M.L.; Alves L.P.; Sales V.A.W.; Barbosa I.N.G.; Andrade M.C.; Santos W.M.; Rolim L.A.; Rolim-Neto P.J.; Drug associations as alternative and complementary therapy for neglected tropical diseases. Acta Trop  2022,225,106210","journal-title":"Acta Trop"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40262-016-0467-3","volume":"56","author":"Verrest L.","year":"2017","unstructured":"Verrest L.; Dorlo T.P.C.; Lack of clinical pharmacokinetic studies to optimize the treatment of neglected tropical diseases: a systematic review. Clin Pharmacokinet  2017,56(6),583-606","journal-title":"Clin Pharmacokinet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.molbiopara.2018.12.005","volume":"228","author":"Sanchez M.C.","year":"2019","unstructured":"Sanchez M.C.; Cupit P.M.; Bu L.; Cunningham C.; Transcriptomic analysis of reduced sensitivity to praziquantel in Schistosoma mansoni. Mol Biochem Parasitol  2019,228,6-15","journal-title":"Mol Biochem Parasitol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2174\/1568026620666200924115113","volume":"21","author":"Oliveira N.F.","year":"2021","unstructured":"Oliveira N.F.; Silva C.L.M.; Unveiling the potential of purinergic signaling in schistosomiasis treatment. Curr Top Med Chem  2021,21(3),193-204","journal-title":"Curr Top Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/jac\/dkx516","volume":"73","author":"Aldasoro E.","year":"2018","unstructured":"Aldasoro E.; Posada E.; Requena-M\u00e9ndez A.; Calvo- Cano A.; Serret N.; Casellas A.; Sanz S.; Soy D.; Pinazo M.J.; Gascon J.; What to expect and when: benznidazole toxicity in chronic Chagas\u2019 disease treatment. J Antimicrob Chemother  2018,73(4),1060-1067","journal-title":"J Antimicrob Chemother"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1056\/NEJMe1510170","volume":"373","author":"Maguire J.H.","year":"2015","unstructured":"Maguire J.H.; Treatment of chagas\u2019 disease - time is running out. N Engl J Med  2015,373(14),1369-1370","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/17425247.2022.2051477","volume":"19","author":"Mengarda A.C.","year":"2022","unstructured":"Mengarda A.C.; Iles B.; F Longo J.P.; de Moraes J.; Recent trends in praziquantel nanoformulations for helminthiasis treatment. Expert Opin Drug Deliv  2022,19(4),383-393","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2174\/0929867327666200219141652","volume":"28","author":"Maheshwari K.K.","year":"2021","unstructured":"Maheshwari K.K.; Bandyopadhyay D.; Heterocycles in the treatment of neglected tropical diseases. Curr Med Chem  2021,28(3),472-495","journal-title":"Curr Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e0185033","DOI":"10.1371\/journal.pone.0185033","volume":"12","author":"Olivera M.J.","year":"2017","unstructured":"Olivera M.J.; Cucunub\u00e1 Z.M.; Valencia-Hern\u00e1ndez C.A.; Herazo R.; Agreda-Rudenko D.; Fl\u00f3rez C.; Duque S.; Nicholls R.S.; Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. PLoS One  2017,12(9),e0185033","journal-title":"PLoS One"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1016\/j.bmc.2017.04.031","volume":"25","author":"da Silva V.B.R.","year":"2017","unstructured":"da Silva V.B.R.; Campos B.R.K.L.; de Oliveira J.F.; Decout J.L.; do Carmo Alves de Lima M.; Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine. Bioorg Med Chem  2017,25(13),3259-3277","journal-title":"Bioorg Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jconrel.2021.09.020","volume":"339","author":"Joshi G.","year":"2021","unstructured":"Joshi G.; Quadir S.S.; Yadav K.S.; Road map to the treatment of neglected tropical diseases: Nanocarriers interventions. J Control Release  2021,339,51-74","journal-title":"J Control Release"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.biomaterials.2013.10.044","volume":"35","author":"Zhao F.","year":"2014","unstructured":"Zhao F.; Yin H.; Li J.; Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug. Biomaterials  2014,35(3),1050-1062","journal-title":"Biomaterials"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","volume":"535","author":"Jansook P.","year":"2018","unstructured":"Jansook P.; Ogawa N.; Loftsson T.; Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. Int J Pharm  2018,535(1-2),272-284","journal-title":"Int J Pharm"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"115805","DOI":"10.1016\/j.carbpol.2019.115805","volume":"232","author":"Tian B.","year":"2020","unstructured":"Tian B.; Hua S.; Liu J.; Cyclodextrin-based delivery systems for chemotherapeutic anticancer drugs: A review. Carbohydr Polym  2020,232,115805","journal-title":"Carbohydr Polym"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ijpharm.2015.11.026","volume":"496","author":"Arr\u00faa E.C.","year":"2015","unstructured":"Arr\u00faa E.C.; Ferreira M.J.G.; Salomon C.J.; Nunes T.G.; Elucidating the guest-host interactions and complex formation of praziquantel and cyclodextrin derivatives by 13 C and 15 N solid-state NMR spectroscopy. Int J Pharm  2015,496(2),812-821","journal-title":"Int J Pharm"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/molecules23051161","volume":"23","author":"Saokham P.","year":"2018","unstructured":"Saokham P.; Muankaew C.; Jansook P.; Loftsson T.; Solubility of cyclodextrins and drug\/cyclodextrin complexes. Molecules  2018,23(5),1161","journal-title":"Molecules"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bcpt.12917","volume":"122","author":"Muankaew C.","year":"2018","unstructured":"Muankaew C.; Loftsson T.; Cyclodextrin-based formulations: a non-invasive platform for targeted drug delivery. Basic Clin Pharmacol Toxicol  2018,122(1),46-55","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ijpharm.2017.07.046","volume":"531","author":"Schwarz D.H.","year":"2017","unstructured":"Schwarz D.H.; Engelke A.; Wenz G.; Solubilizing steroidal drugs by \u03b2-cyclodextrin derivatives. Int J Pharm  2017,531(2),559-567","journal-title":"Int J Pharm"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ijpharm.2017.06.009","volume":"531","author":"Popielec A.","year":"2017","unstructured":"Popielec A.; Loftsson T.; Effects of cyclodextrins on the chemical stability of drugs. Int J Pharm  2017,531(2),532-542","journal-title":"Int J Pharm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"Page M.J.","year":"2021","unstructured":"Page M.J.; McKenzie J.E.; Bossuyt P.M.; Boutron I.; Hoffmann T.C.; Mulrow C.D.; Shamseer L.; Tetzlaff J.M.; Akl E.A.; Brennan S.E.; Chou R.; Glanville J.; Grimshaw J.M.; Hr\u00f3bjartsson A.; Lalu M.M.; Li T.; Loder E.W.; Mayo-Wilson E.; McDonald S.; McGuinness L.A.; Stewart L.A.; Thomas J.; Tricco A.C.; Welch V.A.; Whiting P.; Moher D.; The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ  2021,372,n71","journal-title":"BMJ"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"Ouzzani M.","year":"2016","unstructured":"Ouzzani M.; Hammady H.; Fedorowicz Z.; Elmagarmid A.; Rayyan-a web and mobile app for systematic reviews. Syst Rev  2016,5(1),210","journal-title":"Syst Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2174\/1381612827666210804104205","volume":"28","author":"de Souza M.L.","year":"2022","unstructured":"de Souza M.L.; de Albuquerque Wanderley Sales V.; Alves L.P.; dos Santos W.M.; de Moura Ferraz L.R.; de Andrade Lima G.S.; dos Santos Mendes L.M.; Rolim L.A.; Neto P.J.R.; A systematic review of functionalized polymeric nanoparticles to improve intestinal permeability of drugs and biological products. Curr Pharm Des  2022,28(5),410-426","journal-title":"Curr Pharm Des"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.toxlet.2009.05.013","volume":"189","author":"Schneider K.","year":"2009","unstructured":"Schneider K.; Schwarz M.; Burkholder I.; Kopp-Schneider A.; Edler L.; Kinsner-Ovaskainen A.; Hartung T.; Hoffmann S.; \u201cToxRTool\u201d, a new tool to assess the reliability of toxicological data. Toxicol Lett  2009,189(2),138-144","journal-title":"Toxicol Lett"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.2174\/1389450121666200615150039","volume":"21","author":"Lachowicz M.","year":"2020","unstructured":"Lachowicz M.; Sta\u0144czak A.; Ko\u0142odziejczyk M.; Characteristic of cyclodextrins: their role and use in the pharmaceutical technology. Curr Drug Targets  2020,21(14),1495-1510","journal-title":"Curr Drug Targets"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","volume":"392","author":"Burza S.","year":"2018","unstructured":"Burza S.; Croft S.L.; Boelaert M.; Leishmaniasis. Lancet  2018,392(10151),951-970","journal-title":"Lancet"},{"key":"ref=31","unstructured":"Drugs for neglected diseases initiative, leishmaniasis. 2018. Available from:  https:\/\/dndi.org\/wp-\ncontent\/uploads\/2018\/12\/Factsheet2018_Leishmaniasis.pdf (accessed on 13-6-2024)."},{"key":"ref=32","year":"2022","unstructured":"World Health Organization, Leishmaniasis.  Available from:  https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/gho-ntd-leishmaniasis#:~:text=Out%20of%20200%20countries%20and,are%20endemic%20for%20CL%20only.(accessed on 13-6-2024)2022"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(18)33077-0","volume":"393","author":"Depaquit J.","year":"2019","unstructured":"Depaquit J.; Gay F.; Kaltenbach M.L.; Leishmaniasis. Lancet  2019,393(10174),871-872","journal-title":"Lancet"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e0004349","DOI":"10.1371\/journal.pntd.0004349","volume":"10","author":"Akhoundi M.","year":"2016","unstructured":"Akhoundi M.; Kuhls K.; Cannet A.; Vot\u00fdpka J.; Marty P.; Delaunay P.; Sereno D.; A historical overview of the classification, evolution, and dispersion of leishmania parasites and sandflies. PLoS Negl Trop Dis  2016,10(3),e0004349","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41564-018-0154-2","volume":"3","author":"Bates P.A.","year":"2018","unstructured":"Bates P.A.; Revising leishmania\u2019s life cycle. Nat Microbiol  2018,3(5),529-530","journal-title":"Nat Microbiol"},{"key":"ref=36","first-page":"187","year":"2019","unstructured":"Manual of procedures for leishmaniases surveillance and control in the Americas.  2019,187"},{"key":"ref=37","first-page":"186","year":"2010","unstructured":"Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases  2010,186","journal-title":"Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DDDT.S146521","volume":"12","author":"Ghorbani M.","year":"2017","unstructured":"Ghorbani M.; Farhoudi R.; Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther  2017,12,25-40","journal-title":"Drug Des Devel Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","volume":"11","author":"Homayun B.","year":"2019","unstructured":"Homayun B.; Lin X.; Choi H.J.; Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics  2019,11(3),129","journal-title":"Pharmaceutics"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jconrel.2020.04.006","volume":"322","author":"Xu Y.","year":"2020","unstructured":"Xu Y.; Shrestha N.; Pr\u00e9at V.; Beloqui A.; Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. J Control Release  2020,322,486-508","journal-title":"J Control Release"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.actatropica.2016.02.017","volume":"158","author":"Bhattacharya P.","year":"2016","unstructured":"Bhattacharya P.; Mondal S.; Basak S.; Das P.; Saha A.; Bera T.; In Vitro susceptibilities of wild and drug resistant Leishmania donovani amastigotes to piperolactam A loaded hydroxypropyl-\u03b2-cyclodextrin nanoparticles. Acta Trop  2016,158,97-106","journal-title":"Acta Trop"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijpharm.2012.09.039","volume":"439","author":"De Paula E.E.B.","year":"2012","unstructured":"De Paula E.E.B.; De Sousa F.B.; Da Silva J.C.C.; Fernandes F.R.; Melo M.N.; Fr\u00e9zard F.; Grazul R.M.; Sinisterra R.D.; Machado F.C.; Insights into the multi-equilibrium, superstructure system based on \u03b2-cyclodextrin and a highly water soluble guest. Int J Pharm  2012,439(1-2),207-215","journal-title":"Int J Pharm"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"12243","DOI":"10.1038\/s41598-020-69276-5","volume":"10","author":"Parvez S.","year":"2020","unstructured":"Parvez S.; Yadagiri G.; Gedda M.R.; Singh A.; Singh O.P.; Verma A.; Sundar S.; Mudavath S.L.; Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Rep  2020,10(1),12243","journal-title":"Sci Rep"},{"key":"ref=44","doi-asserted-by":"publisher","unstructured":"Parvez, S.; Yadagiri, G.; Arora, K. Coalition of biological agent (melatonin) with chemotherapeutic agent (amphotericin B) for combating visceral leishmaniasis via oral administration of modified solid lipid nanoparticles. ACS Biomater. Sci. Eng., 2021.","DOI":"10.1021\/ACSBIOMATERIALS.1C00859"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.biopha.2015.10.028","volume":"76","author":"Balaraman K.","year":"2015","unstructured":"Balaraman K.; Vieira N.C.; Moussa F.; Vacus J.; Cojean S.; Pomel S.; Bories C.; Figad\u00e8re B.; Kesavan V.; Loiseau P.M.; In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl \u03b2-cyclodextrin formulation and pharmacokinetics via intravenous route. Biomed Pharmacother  2015,76,127-133","journal-title":"Biomed Pharmacother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"119764","DOI":"10.1016\/j.ijpharm.2020.119764","volume":"589","author":"Pinto L.M.A.","year":"2020","unstructured":"Pinto L.M.A.; Adeoye O.; Thomasi S.S.; Francisco A.P.; Carvalheiro M.C.; Cabral-Marques H.; Preparation and characterization of a synthetic curcumin analog inclusion complex and preliminary evaluation of in vitro antileishmanial activity. Int J Pharm  2020,589,119764","journal-title":"Int J Pharm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fcimb.2018.00303","volume":"8","author":"Petersen A.L.O.A.","year":"2018","unstructured":"Petersen A.L.O.A.; Campos T.A.; Dantas D.A.S.; Rebou\u00e7as J.S.; da Silva J.C.; de Menezes J.P.B.; Formiga F.R.; de Melo J.V.; Machado G.; Veras P.S.T.; Encapsulation of the HSP-90 chaperone inhibitor 17-AAG in stable liposome allow increasing the therapeutic index as assessed, in vitro, on Leishmania (L) amazonensis amastigotes-hosted in mouse CBA macrophages. Front Cell Infect Microbiol  2018,8,303","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.rvsc.2018.06.013","volume":"119","author":"Carvalho S.G.","year":"2018","unstructured":"Carvalho S.G.; Siqueira L.A.; Zanini M.S.; dos Santos Matos A.P.; Quaresma C.H.; da Silva L.M.; de Andrade S.F.; Severi J.A.; Villanova J.C.O.; Physicochemical and in vitro biological evaluations of furazolidone-based \u03b2-cyclodextrin complexes in Leishmania amazonensis. Res Vet Sci  2018,119,143-153","journal-title":"Res Vet Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1007\/s13346-020-00841-1","volume":"10","author":"Carvalho S.G.","year":"2020","unstructured":"Carvalho S.G.; Cipriano D.F.; de Freitas J.C.C.; Junior M.\u00c2.S.; Ocaris E.R.Y.; Teles C.B.G.; de Jesus Gouveia A.; Rodrigues R.P.; Zanini M.S.; Villanova J.C.O.; Physicochemical characterization and in vitro biological evaluation of solid compounds from furazolidone-based cyclodextrins for use as leishmanicidal agents. Drug Deliv Transl Res  2020,10(6),1788-1809","journal-title":"Drug Deliv Transl Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijpharm.2014.07.004","volume":"473","author":"Ruiz H.K.","year":"2014","unstructured":"Ruiz H.K.; Serrano D.R.; Dea-Ayuela M.A.; Bilbao-Ramos P.E.; Bol\u00e1s-Fern\u00e1ndez F.; Torrado J.J.; Molero G.; New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp. Int J Pharm  2014,473(1-2),148-157","journal-title":"Int J Pharm"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"122615","DOI":"10.1016\/j.ijpharm.2023.122615","volume":"633","author":"Abpeikar Z.","year":"2023","unstructured":"Abpeikar Z.; Safaei M.; Akbar Alizadeh A.; Goodarzi A.; Hatam G.; The novel treatments based on tissue engineering, cell therapy and nanotechnology for cutaneous leishmaniasis. Int J Pharm  2023,633,122615","journal-title":"Int J Pharm"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"108554","DOI":"10.1016\/j.exppara.2023.108554","volume":"251","author":"Afonso R.C.","year":"2023","unstructured":"Afonso R.C.; Yien R.M.K.; de Siqueira L.B.O.; Simas N.K.; dos Santos Matos A.P.; Ricci-J\u00fanior E.; Promising natural products for the treatment of cutaneous leishmaniasis: A review of in vitro and in vivo studies. Exp Parasitol  2023,251,108554","journal-title":"Exp Parasitol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.onano.2023.100158","volume":"12","author":"Maza Vega D.","year":"2023","unstructured":"Maza Vega D.; Di Meglio M.; Alonso S.V.; Alvira F.; Montanari J.; Nanomaterials for diagnosis, treatment, and prevention of human cutaneous leishmaniasis: A review. OpenNano  2023,12,100158","journal-title":"OpenNano"},{"key":"ref=54","unstructured":"Pan American Health Organization, Chagas disease. 2022. Available from:\n https:\/\/www.paho.org\/en\/topics\/chagas-\ndisease"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.tmaid.2022.102284","volume":"47","author":"Navarro M.","year":"2022","unstructured":"Navarro M.; Reguero L.; Subir\u00e0 C.; Bl\u00e1zquez-P\u00e9rez A.; Requena-M\u00e9ndez A.; Estimating chagas disease prevalence and number of underdiagnosed, and undertreated individuals in Spain. Travel Med Infect Dis  2022,47,102284","journal-title":"Travel Med Infect Dis"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"106930","DOI":"10.1016\/j.actatropica.2023.106930","volume":"243","author":"Lozada-Yavina R.","year":"2023","unstructured":"Lozada-Yavina R.; Marchant C.; Cancino-Faure B.; Hern\u00e1ndez-Rodr\u00edguez E.W.; C\u00f3rdova-Lepe F.; A description of the epidemiological dynamics of Chagas disease via mathematical modeling. Acta Trop  2023,243,106930","journal-title":"Acta Trop"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0020-7519(01)00153-9","volume":"31","author":"Tyler K.M.","year":"2001","unstructured":"Tyler K.M.; Engman D.M.; The life cycle of Trypanosoma cruzi revisited. Int J Parasitol  2001,31(5-6),472-481","journal-title":"Int J Parasitol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","volume":"391","author":"P\u00e9rez-Molina J.A.","year":"2018","unstructured":"P\u00e9rez-Molina J.A.; Molina I.; Chagas disease. Lancet  2018,391(10115),82-94","journal-title":"Lancet"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"112020","DOI":"10.1016\/j.biopha.2021.112020","volume":"142","author":"Garc\u00eda-Huertas P.","year":"2021","unstructured":"Garc\u00eda-Huertas P.; Cardona-Castro N.; Advances in the treatment of Chagas disease: Promising new drugs, plants and targets. Biomed Pharmacother  2021,142,112020","journal-title":"Biomed Pharmacother"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.idc.2012.03.002","volume":"26","author":"Rassi A.","year":"2012","unstructured":"Rassi A.; Rassi A.; Marcondes de Rezende J.; American trypanosomiasis (Chagas disease). Infect Dis Clin North Am  2012,26(2),275-291","journal-title":"Infect Dis Clin North Am"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.xphs.2023.02.015","volume":"112","author":"Moroni A.B.","year":"2023","unstructured":"Moroni A.B.; Calvo N.L.; Kaufman T.S.; Selected aspects of the analytical and pharmaceutical profiles of nifurtimox. J Pharm Sci  2023,112(6),1523-1538","journal-title":"J Pharm Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.4269\/ajtmh.17-0044","volume":"97","author":"Vinuesa T.","year":"2017","unstructured":"Vinuesa T.; Oliver L.; Elizondo E.; Acarregui A.; Esquisabel A.; Vi\u00f1as M.; Pedraz J.L.; Veciana J.; Ventosa N.; Herr\u00e1ez R.; Benznidazole nanoformulates: a chance to improve therapeutics for chagas disease. Am J Trop Med Hyg  2017,97(5),1469-1476","journal-title":"Am J Trop Med Hyg"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"e0246811","DOI":"10.1371\/journal.pone.0246811","volume":"16","author":"Barbosa J.M.C.","year":"2021","unstructured":"Barbosa J.M.C.; Nicoletti C.D.; da Silva P.B.; Melo T.G.; Futuro D.O.; Ferreira V.F.; Salom\u00e3o K.; Characterization and trypanocidal activity of a \u03b2-lapachone-containing drug carrier. PLoS One  2021,16(3),e0246811","journal-title":"PLoS One"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/cbdd.14040","volume":"99","author":"Guilhon-Simplicio F.","year":"2022","unstructured":"Guilhon-Simplicio F.; Serr\u00e3o C.K.R.; Pinto A.C.S.; Pacheco P.A.F.; Faria R.X.; da Rocha D.R.; Ferreira V.F.; Pereira-Junior R.C.; Matheeussen A.; Ba\u00e1n A.; Kiekens F.; de Meneses Pereira M.; Lima E.S.; Winter H.D.; Cos P.; Semisynthetic triterpenes led to the generation of selective antitrypanosomal lead compounds. Chem Biol Drug Des  2022,99(6),868-883","journal-title":"Chem Biol Drug Des"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.carbpol.2011.08.009","volume":"87","author":"Rojas-Aguirre Y.","year":"2012","unstructured":"Rojas-Aguirre Y.; Castillo I.; Hern\u00e1ndez D.J.; Nogueda-Torres B.; M\u00e1rquez-Navarro A.; Villalobos J.C.; S\u00e1nchez-Bart\u00e9z F.; S\u00e1nchez-Torres L.; Gracia-Mora I.; Castillo R.; Hern\u00e1ndez-Luis F.; Diversity in the supramolecular interactions of 5,6-dichloro-2-(trifluoromethyl)-1H-benzimidazole with modified cyclodextrins: Implications for physicochemical properties and antiparasitic activity. Carbohydr Polym  2012,87(1),471-479","journal-title":"Carbohydr Polym"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"103641","DOI":"10.1016\/j.arabjc.2021.103641","volume":"15","author":"Pozo-Mart\u00ednez J.","year":"2022","unstructured":"Pozo-Mart\u00ednez J.; Salgado F.; Liempi A.; Kemmerling U.; Mera-Adasme R.; Olea-Azar C.; Moncada-Basualto M.; Borges F.; Uriarte E.; Matos M.J.; Synthesis and study of the trypanocidal activity of catechol-containing 3-arylcoumarins, inclusion in \u03b2-cyclodextrin complexes and combination with benznidazole. Arab J Chem  2022,15(3),103641","journal-title":"Arab J Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.carbpol.2018.10.010","volume":"204","author":"Moncada-Basualto M.","year":"2019","unstructured":"Moncada-Basualto M.; Matsuhiro B.; Mansilla A.; Lapier M.; Maya J.D.; Olea-Azar C.; Supramolecular hydrogels of \u03b2-cyclodextrin linked to calcium homopoly-l-guluronate for release of coumarins with trypanocidal activity. Carbohydr Polym  2019,204,170-181","journal-title":"Carbohydr Polym"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"115550","DOI":"10.1016\/j.ejmech.2023.115550","volume":"258","author":"Nascimento I.J.S.","year":"2023","unstructured":"Nascimento I.J.S.; Cavalcanti M.A.T.; de Moura R.O.; Exploring N-myristoyltransferase as a promising drug target against parasitic neglected tropical diseases. Eur J Med Chem  2023,258,115550","journal-title":"Eur J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.tmaid.2022.102282","volume":"47","author":"S\u00e1nchez K.E.","year":"2022","unstructured":"S\u00e1nchez K.E.; Spencer L.M.; Pregnancy-associated malaria: Effects of cytokine and chemokine expression. Travel Med Infect Dis  2022,47,102282","journal-title":"Travel Med Infect Dis"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijid.2022.03.045","volume":"119","author":"Tournoy T.K.","year":"2022","unstructured":"Tournoy T.K.; Rosanas-Urgell A.; Van Esbroeck M.; Bottieau E.; Huits R.; Plasmodium malariae after successful treatment of P. falciparum malaria with artemether-lumefantrine. Int J Infect Dis  2022,119,56-58","journal-title":"Int J Infect Dis"},{"key":"ref=71","year":"2021","unstructured":"World Health Organization (2021) Word Malaria Report 2021.  Available from:  https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2021(accessed on 13-6-2024)2021"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"e11902","DOI":"10.1016\/j.heliyon.2022.e11902","volume":"8","author":"Raghavendra K.","year":"2022","unstructured":"Raghavendra K.; Rahi M.; Verma V.; Velamuri P.S.; Kamaraju D.; Baruah K.; Chhibber-Goel J.; Sharma A.; Insecticide resistance status of malaria vectors in the malaria endemic states of India: implications and way forward for malaria elimination. Heliyon  2022,8(12),e11902","journal-title":"Heliyon"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ijpharm.2017.04.042","volume":"526","author":"Rai M.","year":"2017","unstructured":"Rai M.; Ingle A.P.; Paralikar P.; Gupta I.; Medici S.; Santos C.A.; Recent advances in use of silver nanoparticles as antimalarial agents. Int J Pharm  2017,526(1-2),254-270","journal-title":"Int J Pharm"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bios.2018.01.037","volume":"105","author":"Ragavan K.V.","year":"2018","unstructured":"Ragavan K.V.; Kumar S.; Swaraj S.; Neethirajan S.; Advances in biosensors and optical assays for diagnosis and detection of malaria. Biosens Bioelectron  2018,105,188-210","journal-title":"Biosens Bioelectron"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"114592","DOI":"10.1016\/j.ab.2022.114592","volume":"643","author":"Nate Z.","year":"2022","unstructured":"Nate Z.; Gill A.A.S.; Chauhan R.; Karpoormath R.; Recent progress in electrochemical sensors for detection and quantification of malaria. Anal Biochem  2022,643,114592","journal-title":"Anal Biochem"},{"key":"ref=76","author":"Lacey M-S.","year":"2022","unstructured":"Lacey M-S.; Walter W.T.;  Plasmodium Vivax Malaria  2022","journal-title":"Plasmodium Vivax Malaria"},{"key":"ref=77","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4175851","author":"Djoufounna J.","year":"2022","unstructured":"Djoufounna J.; Mayi M.P.A.; Bamou R.; High Prevalence of Asymptomatic Plasmodium Falciparum Malaria in Makenene, a Locality in the Forest-Savannah Transition Zone, Centre Region of Cameroon. SSRN Electron J  2022","journal-title":"SSRN Electron J"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"111446","DOI":"10.1016\/j.molbiopara.2021.111446","volume":"247","author":"Okagu I.U.","year":"2022","unstructured":"Okagu I.U.; Aguchem R.N.; Ezema C.A.; Ezeorba T.P.C.; Eje O.E.; Ndefo J.C.; Molecular mechanisms of hematological and biochemical alterations in malaria: A review. Mol Biochem Parasitol  2022,247,111446","journal-title":"Mol Biochem Parasitol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1016\/j.celrep.2016.08.001","volume":"16","author":"Ruivo M.T.G.","year":"2016","unstructured":"Ruivo M.T.G.; Vera I.M.; Sales-Dias J.; Meireles P.; Gural N.; Bhatia S.N.; Mota M.M.; Mancio-Silva L.; Host AMPK Is a Modulator of Plasmodium Liver Infection. Cell Rep  2016,16(10),2539-2545","journal-title":"Cell Rep"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.7150\/ijbs.7.1427","volume":"7","author":"Perkins D.J.","year":"2011","unstructured":"Perkins D.J.; Were T.; Davenport G.C.; Kempaiah P.; Hittner J.B.; Ong\u2019echa J.M.; Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci  2011,7(9),1427-1442","journal-title":"Int J Biol Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.reprotox.2022.05.016","volume":"111","author":"Clark R.L.","year":"2022","unstructured":"Clark R.L.; Safety of treating malaria with artemisinin-based combination therapy in the first trimester of pregnancy. Reprod Toxicol  2022,111,204-210","journal-title":"Reprod Toxicol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"11068","DOI":"10.1038\/s41598-020-68082-3","volume":"10","author":"Kotepui M.","year":"2020","unstructured":"Kotepui M.; Kotepui K.U.; De Jesus Milanez G.; Masangkay F.R.; Plasmodium spp. mixed infection leading to severe malaria: a systematic review and meta-analysis. Sci Rep  2020,10(1),11068","journal-title":"Sci Rep"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"106658","DOI":"10.1016\/j.ijantimicag.2022.106658","volume":"60","author":"Li G.","year":"2022","unstructured":"Li G.; Yuan Y.; Zheng S.; Lu C.; Li M.; Tan R.; Zhang H.; Silai R.; Liu R.; Abdallah K.S.; Bacar A.; Xu Q.; Song J.; Wu W.; Deng C.; Artemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Grande Comore island: an open-label, non-randomised controlled trial. Int J Antimicrob Agents  2022,60(4),106658","journal-title":"Int J Antimicrob Agents"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ejpb.2011.12.007","volume":"80","author":"Yam\u00e9ogo J.B.G.","year":"2012","unstructured":"Yam\u00e9ogo J.B.G.; G\u00e8ze A.; Choisnard L.; Putaux J.L.; Gansan\u00e9 A.; Sirima S.B.; Semd\u00e9 R.; Wouessidjewe D.; Self-assembled biotransesterified cyclodextrins as Artemisinin nanocarriers \u2013 I: Formulation, lyoavailability and in vitro antimalarial activity assessment. Eur J Pharm Biopharm  2012,80(3),508-517","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijbiomac.2022.04.170","volume":"211","author":"Zhu W.","year":"2022","unstructured":"Zhu W.; Lv Y.; Yang Q.; Zu Y.; Zhao X.; Artemisinin hydroxypropyl-\u03b2-cyclodextrin inclusion complex loaded with porous starch for enhanced bioavailability. Int J Biol Macromol  2022,211,207-217","journal-title":"Int J Biol Macromol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"125049","DOI":"10.1016\/j.colsurfa.2020.125049","volume":"602","author":"Pawar S.","year":"2020","unstructured":"Pawar S.; Shende P.; Dual drug delivery of cyclodextrin cross-linked artemether and lumefantrine nanosponges for synergistic action using 23 full factorial designs. Colloids Surf A Physicochem Eng Asp  2020,602,125049","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"103434","DOI":"10.1016\/j.jddst.2022.103434","volume":"73","author":"Pongsamart K.","year":"2022","unstructured":"Pongsamart K.; Limwikrant W.; Ruktanonchai U.R.; Charoenthai N.; Puttipipatkhachorn S.; Preparation, characterization and antimalarial activity of dihydroartemisinin \/ \u03b2-cyclodextrin spray-dried powder. J Drug Deliv Sci Technol  2022,73,103434","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00436-020-06963-2","volume":"120","author":"Queiroz L.S.","year":"2021","unstructured":"Queiroz L.S.; Ferreira E.A.; Mengarda A.C.; Almeida A.C.; Pinto P.F.; Coimbra E.S.; de Moraes J.; Denadai \u00c2.M.L.; Da Silva Filho A.A.; In vitro and in vivo evaluation of cnicin from blessed thistle (Centaurea benedicta) and its inclusion complexes with cyclodextrins against Schistosoma mansoni. Parasitol Res  2021,120(4),1321-1333","journal-title":"Parasitol Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00436-012-3237-7","volume":"112","author":"Liu M.","year":"2013","unstructured":"Liu M.; Chen P.; B\u00fcchele B.; Dong S.; Huang D.; Ren C.; Zhang Y.; Hou X.; Simmet T.; Shen J.; A boswellic acid-containing extract attenuates hepatic granuloma in C57BL\/6 mice infected with Schistosoma japonicum. Parasitol Res  2013,112(3),1105-1111","journal-title":"Parasitol Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1016\/j.bmc.2015.02.010","volume":"23","author":"Cowan N.","year":"2015","unstructured":"Cowan N.; Yaremenko I.A.; Krylov I.B.; Terent\u2019ev A.O.; Keiser J.; Elucidation of the in vitro and in vivo activities of bridged 1,2,4-trioxolanes, bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, silyl peroxides, and hydroxylamine derivatives against Schistosoma mansoni. Bioorg Med Chem  2015,23(16),5175-5181","journal-title":"Bioorg Med Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1248\/bpb1978.5.741","volume":"5","author":"Irie T.","year":"1982","unstructured":"Irie T.; Otagiri M.; Sunada M.; Uekama K.; Ohtani Y.; Yamada Y.; Sugiyama Y.; Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J Pharmacobiodyn  1982,5(9),741-744","journal-title":"J Pharmacobiodyn"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ddr.21452","volume":"79","author":"Jacob S.","year":"2018","unstructured":"Jacob S.; Nair A.B.; Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev Res  2018,79(5),201-217","journal-title":"Drug Dev Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2016.11.004","volume":"111","author":"Zarmpi P.","year":"2017","unstructured":"Zarmpi P.; Flanagan T.; Meehan E.; Mann J.; Fotaki N.; Biopharmaceutical aspects and implications of excipient variability in drug product performance. Eur J Pharm Biopharm  2017,111,1-15","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1517\/17425247.2014.877442","volume":"11","author":"Gao H.","year":"2014","unstructured":"Gao H.; He Q.; The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior. Expert Opin Drug Deliv  2014,11(3),409-420","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=95","unstructured":"World Health Organization, Schistosomiasis. 2022. Available from:\n https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schistosomiasis"},{"key":"ref=96","unstructured":"World Health Organization, Schistosomiasis and soil-transmitted helminthiase: progress report, 2020. 2021. Available from:  https:\/\/www.who.int\/publications\/i\/item\/who-wer9748-621-632 (accessed on 13-6-2024)."},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1812165","volume":"381","author":"Deol A.K.","year":"2019","unstructured":"Deol A.K.; Fleming F.M.; Calvo-Urbano B.; Walker M.; Bucumi V.; Gnandou I.; Tukahebwa E.M.; Jemu S.; Mwingira U.J.; Alkohlani A.; Traor\u00e9 M.; Ruberanziza E.; Tour\u00e9 S.; Bas\u00e1\u00f1ez M.G.; French M.D.; Webster J.P.; Schistosomiasis - assessing progress toward the 2020 and 2025 global goals. N Engl J Med  2019,381(26),2519-2528","journal-title":"N Engl J Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40249-022-00995-9","volume":"11","author":"Li Y.L.","year":"2022","unstructured":"Li Y.L.; Dang H.; Guo S.Y.; Zhang L.J.; Feng Y.; Ding S.J.; Shan X.W.; Li G.P.; Yuan M.; Xu J.; Li S.Z.; Molecular evidence on the presence of Schistosoma japonicum infection in snails along the Yangtze River, 2015\u20132019. Infect Dis Poverty  2022,11(1),70","journal-title":"Infect Dis Poverty"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","volume":"4","author":"McManus D.P.","year":"2018","unstructured":"McManus D.P.; Dunne D.W.; Sacko M.; Utzinger J.; Vennervald B.J.; Zhou X.N.; Schistosomiasis. Nat Rev Dis Primers  2018,4(1),13","journal-title":"Nat Rev Dis Primers"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"P2431","DOI":"10.1016\/S0140-6736(18)33008-3","volume":"392","author":"Barnett R.","year":"2018","unstructured":"Barnett R.; Case histories schistosomiasis. The Lancet  2018,392(10163),P2431","journal-title":"The Lancet"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"111531","DOI":"10.1016\/j.molbiopara.2022.111531","volume":"252","author":"Nogueira R.A.","year":"2022","unstructured":"Nogueira R.A.; Lira M.G.S.; Lic\u00e1 I.C.L.; Fraz\u00e3o G.C.C.G.; dos Santos V.A.F.; Filho A.C.C.M.; Rodrigues J.G.M.; Miranda G.S.; Carvalho R.C.; Nascimento F.R.F.; Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. Mol Biochem Parasitol  2022,252,111531","journal-title":"Mol Biochem Parasitol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.01.033","volume":"295","author":"Dinora G-E.","year":"2005","unstructured":"Dinora G-E.; Julio R.; Nelly C.; Lilian Y-M.; Cook H.J.; In vitro characterization of some biopharmaceutical properties of praziquantel. Int J Pharm  2005,295(1-2),93-99","journal-title":"Int J Pharm"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/pharmaceutics12100914","volume":"12","author":"Borrego-S\u00e1nchez A.","year":"2020","unstructured":"Borrego-S\u00e1nchez A.; S\u00e1nchez-Espejo R.; Garc\u00eda-Vill\u00e9n F.; Viseras C.; Sainz-D\u00edaz C.I.; Praziquantel\u2013clays as accelerated release systems to enhance the low solubility of the drug. Pharmaceutics  2020,12(10),914","journal-title":"Pharmaceutics"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/26895293.2022.2080281","volume":"15","author":"Mtemeli F.L.","year":"2022","unstructured":"Mtemeli F.L.; Ndlovu J.; Mugumbate G.; Makwikwi T.; Shoko R.; Advances in schistosomiasis drug discovery based on natural products. All Life  2022,15(1),608-623","journal-title":"All Life"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.actatropica.2017.08.002","volume":"176","author":"Siqueira L.P.","year":"2017","unstructured":"Siqueira L.P.; Fontes D.A.F.; Aguilera C.S.B.; Tim\u00f3teo T.R.R.; \u00c2ngelos M.A.; Silva L.C.P.B.B.; de Melo C.G.; Rolim L.A.; da Silva R.M.F.; Neto P.J.R.; Schistosomiasis: Drugs used and treatment strategies. Acta Trop  2017,176,179-187","journal-title":"Acta Trop"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.4049\/jimmunol.0900521","volume":"183","author":"Wang H.","year":"2009","unstructured":"Wang H.; Syrovets T.; Kess D.; B\u00fcchele B.; Hainzl H.; Lunov O.; Weiss J.M.; Scharffetter-Kochanek K.; Simmet T.; Targeting NF-\u03ba B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J Immunol  2009,183(7),4755-4763","journal-title":"J Immunol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10847-019-00880-3","volume":"93","author":"Montenegro Rabello M.","year":"2019","unstructured":"Montenegro Rabello M.; Rolim L.A.; Rolim Neto P.J.; Hernandes M.Z.; CycloMolder software: building theoretical cyclodextrin derivatives models and evaluating their host:guest interactions. J Incl Phenom Macrocycl Chem  2019,93(3-4),301-308","journal-title":"J Incl Phenom Macrocycl Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673318410240627031819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/231564\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673318410240627031819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:23:29Z","timestamp":1751624609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/231564\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":107,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673318410240627031819","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}